Clarity Pharma rallies after completing enrolment for diagnostic study
Make us a preferred source
Make us a preferred source on Google
The news: Shares in Clarity Pharmaceuticals soared in early trading after the biotech company announced it has completed recruitment for a new study evaluating the performance of its imaging agent Cu-SAR-bisPSMA, a novel diagnostic option for patients with prostate cancer.
The numbers: Clarity shares were up 5.6% to $3.60 at 10:45am AEST, having jumped more than 9% at the open.
The context: The study will evaluate the diagnostic treatment for the detection of prostate cancer recurrence in patients with low prostate-specific antigen (PSA), who are candidates for curative salvage therapy.
The study is a prospective, phase two imaging trial in 50 patients.
What they said: "The high volume of patients imaged in recent months at a single site reflects the high unmet need for more effective diagnostic tools for men with rising PSA following radical prostatectomy," said Clarity executive chairman Alan Taylor.
"Visualising cancer early in these patients is crucial for physicians to determine the optimal course of treatment before the cancer spreads, leading to improved outcomes, including the potential for cure."
The source: ASX
